Salvage Radiotherapy After Postprostatectomy Biochemical Failure: Does Pretreatment Radioimmunoscintigraphy Help Select Patients with Locally Confined Disease?

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 5, 2008, Pages 1316-1321

  Liauw, Stanley L ^a   Weichselbaum, Ralph R ^a   Zagaja, Gregory P ^a   Jani, Ashesh B ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer; Radioimmunoscintigraphy; Radiotherapy

Indexed keywords

ELECTROTHERAPEUTICS; PATIENT MONITORING; PEELING; RADIOTHERAPY; TURBULENT FLOW;

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL CONTROL; BIOCHEMICAL CONTROL RATE; BIOCHEMICAL FAILURES; GLEASON SCORE; LYMPH NODE; PRE TREATMENTS; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; RADIOIMMUNOSCINTIGRAPHY; SALVAGE RADIOTHERAPY; UNIVARIATE;

INTERLOCKING SIGNALS;

ANTIANDROGEN; CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; IMMUNOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIATION DOSE; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 47149098579     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.11.053     Document Type: Article

References (43)

1. Jani A.B., and Hellman S. Early prostate cancer: Clinical decision-making. Lancet 361 (2003) 1045-1053
2. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167 (2002) 528-534
3. Karakiewicz P.I., Eastham J.A., Graefen M., et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: Multi-institutional assessment of 5831 patients. Urology 66 (2005) 1245-1250
4. Orvieto M.A., Alsikafi N.F., Shalhav A.L., et al. Impact of surgical margin status on long-term cancer control after radical prostatectomy. BJU Int 98 (2006) 1199-1203
5. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172 (2004) 910-914
6. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
7. Brooks J.P., Albert P.S., Wilder R.B., et al. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J Urol 174 (2005) 2204-2208
8. Buskirk S.J., Pisansky T.M., Schild S.E., et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 176 (2006) 985-990
9. Cheung R., Kamat A.M., de Crevoisier R., et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 63 (2005) 134-140
10. Katz M.S., Zelefsky M.J., Venkatraman E.S., et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21 (2003) 483-489
11. King C.R., Presti Jr. J.C., Gill H., et al. Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys 59 (2004) 341-347
12. MacDonald O.K., Schild S.E., Vora S., et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: Do outcomes differ?. Urology 64 (2004) 760-764
13. Maier J., Forman J., Tekyi-Mensah S., et al. Salvage radiation for a rising PSA following radical prostatectomy. Urol Oncol 22 (2004) 50-56
14. Neuhof D., Hentschel T., Bischof M., et al. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 67 (2007) 1411-1417
15. Pacholke H.D., Wajsman Z., Algood C.B., et al. Postoperative adjuvant and salvage radiotherapy for prostate cancer: Impact on freedom from biochemical relapse and survival. Urology 64 (2004) 982-986
16. Pazona J.F., Han M., Hawkins S.A., et al. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 174 (2005) 1282-1286
17. Spiotto M.T., Hancock S.L., and King C.R. Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69 (2007) 54-61
18. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007) 2035-2041
19. Warren K.S., Chodak G.W., See W.A., et al. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?. J Urol 176 (2006) 70-74 2006
20. Kane C.J., Amling C.L., Johnstone P.A., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61 (2003) 607-611
21. Bander N.H. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3 (2006) 216-225
22. Jani A.B., Liauw S.L., and Blend M.J. The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clin Med Res 5 (2007) 123-131
23. Sodee D.B., Malguria N., Faulhaber P., et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer: The ProstaScint imaging centers. Urology 56 (2000) 988-993
24. Noz M.E., Chung G., Lee B.Y., et al. Enhancing the utility of ProstaScint SPECT scans for patient management. J Med Syst 30 (2006) 123-132
25. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 159 (1998) 2041-2047
26. Proano J.M., Sodee D.B., Resnick M.I., et al. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol 175 (2006) 1668-1672
27. 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 834-840
28. Thomas C.T., Bradshaw P.T., Pollock B.H., et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 21 (2003) 1715-1721
29. 111Indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol 172 (2004) 133-136
30. Jani A.B., Blend M.J., Hamilton R., et al. Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med 45 (2004) 571-578
31. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
32. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296 (2006) 2329-2335
33. Pisansky T.M., Pollack A., Sandler H.M., et al. Advanced prostate cancer and postoperative radiotherapy. JAMA 297 (2007) 950-951
34. Jani A.B., and Kao J. Postprostatectomy adjuvant versus salvage radiotherapy: A complication-adjusted number-needed-to-treat analysis. Cancer 103 (2005) 1833-1842
35. Levesque P.E., Nieh P.T., Zinman L.N., et al. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 51 (1998) 978-984
36. Jani A.B., Spelbring D., Hamilton R., et al. Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. J Nucl Med 45 (2004) 238-246
37. Jani A.B., Blend M.J., Hamilton R., et al. Radioimmunoscintigraphy for postprostatectomy radiotherapy: Analysis of toxicity and biochemical control. J Nucl Med 45 (2004) 1315-1322
38. Sella T., Schwartz L.H., Swindle P.W., et al. Suspected local recurrence after radical prostatectomy: Endorectal coil MR imaging. Radiology 231 (2004) 379-385
39. Choi Y.J., Kim J.K., Kim N., et al. Functional MR imaging of prostate cancer. Radiographics 27 (2007) 63-77
40. Sandblom G., Sorensen J., Lundin N., et al. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67 (2006) 996-1000
41. Vees H., Buchegger F., Albrecht S., et al. 18F-choline and/or 11C-acetate positron emission tomography: Detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99 (2007) 1415-1420
42. Hricak H., Choyke P.L., Eberhardt S.C., et al. Imaging prostate cancer: A multidisciplinary perspective. Radiology 243 (2007) 28-53
43. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499